Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Oh the Places You’ll Go (with 1 billion regressions an hour) explores the partnership with Alnylam to access and understand the data from the UK Biobank project. Click the image below to view the full video:
BOSTON — Paradigm4 has today unveiled REVEAL™: Proteomics, the newest use case specific app powered by the Paradigm4 FLASH™ high-performance bioinformatics platform. REVEAL: Proteomics unlocks the power of advanced mass spec proteomics by simplifying cross sample and cross study searching for protein isoforms as potential biomarkers for drug response or
Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.
